Search Results

You are looking at 31 - 40 of 1,474 items for :

  • metabolic disease x
  • Refine by Access: All content x
Clear All
Free access

Xiao-Bing Cui, Jun-Na Luan, Jianping Ye, and Shi-You Chen

TK Basford JE Knoll E Tong WS Blanco V Blomkalns AL Rudich S Lentsch AB Hui DY Weintraub NL 2014 HDAC9 knockout mice are protected from adipose tissue dysfunction and systemic metabolic disease during high-fat feeding . Diabetes

Free access

Laura D Ratner, Guillermina Stevens, Maria Marta Bonaventura, Victoria A Lux-Lantos, Matti Poutanen, Ricardo S Calandra, Ilpo T Huhtaniemi, and Susana B Rulli

Metabolic syndrome pandemic . Arteriosclerosis, Thrombosis, and Vascular Biology 28 629 – 636 . ( doi:10.1161/ATVBAHA.107.151092 ) Guo S 2014 Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease

Free access

Antonios Chatzigeorgiou, Eleni Kandaraki, Christina Piperi, Sarantis Livadas, Athanasios G Papavassiliou, Michael Koutsilieris, Apostolos Papalois, and Evanthia Diamanti-Kandarakis

pathogenesis of other diseases such as atherosclerosis, chronic renal failure, polycystic ovary syndrome (PCOS) and Alzheimer's disease ( Mukhopadhyay & Mukherjee 2005 , Tan et al . 2011 ). Furthermore, data obtained from humans and experimental animals

Open access

Ashley Patton, Tyler Church, Caroline Wilson, Jean Thuma, Douglas J Goetz, Darlene E Berryman, Edward O List, Frank Schwartz, and Kelly D McCall

of metabolic diseases, specifically obesity-related diseases such as T2DM and NAFLD. Obesity alone is considered the most important risk factor for development of NAFLD and is the driver of inflammation in this disease that is responsible for its

Free access

Margo P Emont, Hui Yu, and Jun Wu

12 21–45 ♂ Chondronikola et al . (2014) and Lee et al . (2014 c ) Concluding remarks In the long pursuit of better understanding and more effective therapeutics for metabolic disease, we have become aware that many of

Free access

Milos Mraz and Martin Haluzik

obesity lies in its interconnection with a number of metabolic and non-metabolic diseases including type 2 diabetes mellitus (T2DM), dyslipidemia, arterial hypertension, and atherosclerosis, leading to substantially increased cardiovascular and

Free access

Mark Nixon, Rita Upreti, and Ruth Andrew

gastrointestinal tract ( Nienstedt et al . 1980 a , b , Normington & Russell 1992 ), all sites of importance in inflammatory diseases and GC therapies. In metabolic tissues, 5αR1 is highly expressed in the liver ( Normington & Russell 1992 , Livingstone et al

Free access

Takeshi Iwasa, Toshiya Matsuzaki, Kiyohito Yano, Yiliyasi Mayila, Rie Yanagihara, Yuri Yamamoto, Akira Kuwahara, and Minoru Irahara

implications for the prevention of future diseases ( Gluckman & Hanson 2004 ). Over the past decade, it has been proposed that the concept of DOHaD may be applicable to the evaluation of PCOS etiology because metabolic derangement with developmental origins is

Free access

Jie Wei, Xia Sun, Yajie Chen, Yuanyuan Li, Liqiong Song, Zhao Zhou, Bing Xu, Yi Lin, and Shunqing Xu

Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the typical hepatic manifestations of metabolic syndrome characterized by hepatic fat accumulation in the absence of excess alcohol consumption. NAFLD affects 15–40% of the general

Free access

Harman S Mattu and Harpal S Randeva

that PVAT has important implications in vascular biology with protective and harmful effects – dependent on the balance of adipokines. Naturally, in metabolic diseases such as diabetes and obesity, the imbalance will set off a chain of adipokine